Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
STOK compared with NGNE: revenue, margins and what each company keeps, and the suppliers and customers both name
STOK
Stoke Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
NGNE
Neurogene Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
STOK
Stoke Therapeutics, Inc.
vs
NGNE
Neurogene Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
STOK
Stoke Therapeutics, Inc.
Change
26.30
▼
−0.19%
· post 26.24
Mkt cap
$1.7B
Revenue
$9M
Q2 FY26
Revenue
$184M
FY25
NGNE
Neurogene Inc.
Change
27.61
▼
−4.20%
· post 27.61
Closed
Oct 30 '26
Mkt cap
$621.3M
Revenue
$925,000
Q2 FY24
Revenue
—
vs
Compare
Closed
Oct 30 '26
STOK
Stoke Therapeutics, Inc.
vs
NGNE
Neurogene Inc.
26.30
▼
−0.19%
post 26.24
Price
27.61
▼
−4.20%
post 27.61
$1.7B
Mkt cap
$621.3M
Q2 FY26
$9M
Revenue
$925,000
Q2 FY24
FY25
$184M
Revenue
—
Change
Change
STOK
26.30
▼
−0.19%
vs
NGNE
27.61
▼
−4.20%
Closed
Oct 30 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
STOK, solid
NGNE, dashed
Supply-chain overlap
Revenue flow
STOK: latest quarter is a loss; flow not drawable. NGNE: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only STOK
3
BIIB
Biogen International GmbH
customer
ACAD
Acadia Pharmaceuticals
customer
—
NWALP PHOP Property Owner
unlisted
supplier
Shared
0
No disclosed counterparties: NGNE.
Only NGNE
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR